CM
SNDX icon

Crestline Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Crestline Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-713,205
Closed -$9.43M – 546
2024
Q4 		$9.43M Buy
713,205
+284,667
+66% +$4.87M 0.31% 54
2024
Q3 		$8.25M Buy
428,538
+285,258
+199% +$5.89M 0.43% 59
2024
Q2 		$2.94M Buy
143,280
+39,570
+38% +$828K 0.23% 115
2024
Q1 		$2.47M Buy
103,710
+3,061
+3% +$68.3K 0.22% 122
2023
Q4 		$2.18M Sell
100,649
-33,815
-25% -$520K 0.19% 130
2023
Q3 		$1.95M Buy
134,464
+22,000
+20% +$416K 0.23% 110
2023
Q2 		$2.35M Buy
112,464
+17,255
+18% +$359K 0.25% 107
2023
Q1 		$2.01M Buy
95,209
+31,002
+48% +$771K 0.24% 99
2022
Q4 		$1.63M Buy
64,207
+656
+1% +$15.3K 0.24% 79
2022
Q3 		$1.53M Buy
63,551
+3,000
+5% +$67.3K 0.21% 92
2022
Q2 		$1.17M Sell
60,551
-2,965
-5% -$49.4K 0.15% 111
2022
Q1 		$1.1M Buy
+63,516
New +$1.07M 0.13% 134
2018
Q3 		– Sell
-35,027
Closed -$246K – 226
2018
Q2 		$246K Sell
35,027
-1,687
-5% -$16.6K 0.03% 228
2018
Q1 		$522K Sell
36,714
-46,425
-56% -$493K 0.06% 192
2017
Q4 		$728K Buy
83,139
+29,607
+55% +$293K 0.07% 127
2017
Q3 		$626K Sell
53,532
-1,836
-3% -$22.5K 0.09% 117
2017
Q2 		$773K Buy
+55,368
New +$633K 0.1% 98

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Crestline Management's SNDX Position: Q1 2025 in Review

Crestline Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2025, closing a stake of 713,205 shares — an estimated $9.43M sold.

Crestline Management first reported a position in SNDX in Q2 2017 and held it in 17 quarters. The position peaked at $9.43M in Q4 2024. 218 funds tracked by Wall St. Rank hold SNDX as of Q1 2025.

  • Crestline Management reported no remaining Syndax Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 713,205 Syndax Pharmaceuticals shares in Q1 2025, an estimated $9.43M.
  • Crestline Management first reported a position in Syndax Pharmaceuticals in Q2 2017 and held it in 17 quarters.
  • Crestline Management's Syndax Pharmaceuticals position peaked at $9.43M in Q4 2024.
  • 218 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.